Central Garden & Pet (CENT) Up 39% in a Year: What Lies in 2022?

Published on December 30, 2021

Central Garden & Pet's (CENT) acquisition initiative constantly strengthens its portfolio. It also steadily advances its digital capabilities and focuses on marketing activities.

Continue reading on website
Other news

J&J (JNJ) Seeks FDA Approval for Myeloma Drug Teclistamab

December 30, 2021
J&J (JNJ) submits a Biologics License Application, seeking approval for its bispecific antibody candidate teclistamab as a treatment option for the heavily pretreated multiple myeloma patients.

G-III Apparel (GIII) Stock Up 21% in a Year: Road Ahead in 2022

December 30, 2021
G-III Apparel's (GIII) brand strength and robust business strategies, including the restructuring initiatives appear encouraging. Its digital business also looks good.